Annals of Surgical Oncology

, Volume 20, Issue 5, pp 1451–1455 | Cite as

Hereditary Medullary Thyroid Cancer: Age-Appropriate Thyroidectomy Improves Disease-Free Survival

  • Kevin Shepet
  • Amal Alhefdhi
  • Ngan Lai
  • Haggi Mazeh
  • Rebecca Sippel
  • Herbert Chen
Endocrine Tumors

Abstract

Background

Twenty-five percent of medullary thyroid cancer (MTC) cases are hereditary. The ideal age for prophylactic thyroidectomy is based on the specific RET mutation involved. The purpose of this study was to determine whether such age-appropriate prophylactic thyroidectomy results in improved disease-free survival.

Methods

Twenty-eight patients underwent thyroidectomy for hereditary MTC at our institution. Age-appropriate thyroidectomy was defined according to the North American Neuroendocrine Tumor Society (NANETS) guidelines. Patients who had age-appropriate surgery (group 1, n = 9) were compared to those who had thyroidectomy past the recommended age (group 2, n = 19).

Results

The mean age was 13 ± 2 years, and 61 % were female. Patients in group 1 were younger than in group 2 (4 ± 1 vs. 17 ± 2 years, p < 0.01). There were no significant differences in gender or RET mutation types between these two groups. Group 1 patients were cured with no disease recurrence compared with group 2 patients who had a 42 % recurrence rate (p = 0.05). Subanalysis of group 2 identified that patients who underwent surgery without evidence of disease did so at a shorter period following the guidelines compared with those who underwent therapeutic surgery (2 ± 2 vs. 16 ± 2 years, p = 0.01) and had longer disease-free survival (100 vs. 27 %, p = 0.005).

Conclusions

Patients with hereditary MTC should undergo age-appropriate thyroidectomy based on RET mutational status to avoid recurrence. Patients who are past the recommended age should have surgery as early as possible to improve disease-free survival.

References

  1. 1.
    Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol. 2007;16(4):237–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Moley JF, Lairmore TC, Phay JE. Hereditary endocrinopathies. Curr Prob Surg. 1999;36(9):653–762.CrossRefGoogle Scholar
  6. 6.
    Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet. 2000;37(11):817–27.PubMedCrossRefGoogle Scholar
  7. 7.
    Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Mol Genet. 1993;2(7):851–6.CrossRefGoogle Scholar
  8. 8.
    Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag. 2008;4(5):935–47.PubMedGoogle Scholar
  9. 9.
    Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype–phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Eng J Med. 2005;353(11):1105–13.CrossRefGoogle Scholar
  12. 12.
    O’Riordain DS, O’Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116(6):1017–23.PubMedGoogle Scholar
  13. 13.
    Schreinemakers JMJ, Vriens MR, Valk GD, et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg. 2010; 34(4):852–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Eng J Med. 2003;349(16):1517–25.CrossRefGoogle Scholar
  15. 15.
    Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Eng J Med. 1973;289(9):437–41.CrossRefGoogle Scholar
  16. 16.
    Kloos R, Eng C, Evans D, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Kevin Shepet
    • 1
  • Amal Alhefdhi
    • 1
  • Ngan Lai
    • 1
  • Haggi Mazeh
    • 1
  • Rebecca Sippel
    • 1
  • Herbert Chen
    • 1
  1. 1.Section of Endocrine Surgery, Department of SurgeryUniversity of WisconsinMadisonUSA

Personalised recommendations